Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 13/20 | 0.45 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.45 |
| ▸ | HSPB1 | P04792 | 2/20 | 0.43 |
| ▸ | LMNA | P02545 | 6/20 | 0.42 |
| ▸ | SMN1; SMN2 | Q16637 | 6/20 | 0.42 |
| ▸ | HTT | P42858 | 3/20 | 0.42 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.40 |
| ▸ | MEN1 | O00255 | 2/20 | 0.40 |
| ▸ | RGS12 | O14924 | 2/20 | 0.40 |
| ▸ | BLM | P54132 | 1/20 | 0.39 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.39 |
| ▸ | APOBEC3A | P31941 | 1/20 | 0.39 |
| ▸ | APOBEC3G | Q9HC16 | 1/20 | 0.39 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.38 |
| ▸ | GAA | P10253 | 3/20 | 0.38 |
| ▸ | CYP19A1 | P11511 | 1/20 | 0.38 |
| ▸ | HPGD | P15428 | 1/20 | 0.38 |
| ▸ | PKM | P14618 | 1/20 | 0.38 |
| ▸ | POLB | P06746 | 1/20 | 0.38 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4955971 | 0.88 | HSPB1 (0.42) | MAPTMAPK1HSPB1LMNASMN1; SMN2 | |
| SCHEMBL4955776 | 0.88 | HSPB1 (0.47) | MAPTMAPK1HSPB1LMNASMN1; SMN2 | |
| SCHEMBL4954080 | 0.87 | HSPB1 (0.43) | MAPTMAPK1HSPB1LMNASMN1; SMN2 | |
| SCHEMBL4952054 | 0.87 | HSPB1 (0.44) | MAPTMAPK1HSPB1LMNASMN1; SMN2 | |
| SCHEMBL4954358 | 0.85 | MAPT (0.46) | MAPTMAPK1HSPB1LMNASMN1; SMN2 | |
| SCHEMBL4951920 | 0.85 | MAPT (0.40) | MAPTMAPK1HSPB1LMNASMN1; SMN2 | |
| SCHEMBL4955575 | 0.85 | KDM4E (0.45) | MAPTKMT2AMEN1ALDH1A1CYP19A1 | |
| SCHEMBL4365552 | 0.85 | HSPB1 (0.48) | MAPTMAPK1HSPB1LMNASMN1; SMN2 | |
| SCHEMBL4375482 | 0.84 | HSPB1 (0.43) | MAPTMAPK1HSPB1LMNASMN1; SMN2 | |
| SCHEMBL4951794 | 0.83 | HSPB1 (0.51) | MAPTMAPK1HSPB1LMNASMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7425568-B2 | Compounds, which are potent inhibitors of Na+ /Ca2+ exchange mechanism and are useful in the treatment of arrhythmias | ORION CORPORATION (FI) | 2008-09-16 | — | — | US | disclosed |
| EP-1412343-B1 | COMPOUNDS, WHICH ARE POTENT INHIBITORS OF NA+/CA2+ EXCHANGE MECHANISM AND ARE USEFUL IN THE TREATMENT OF ARRHYTHMIAS | ORION CORP (FI) | 2006-08-30 | — | — | EP | disclosed |
| US-20040235905-A1 | Compounds, which are potent inhibitors of na+ / ca2+ exchange mechanism and are useful in the treatment of arrhythmias | ORION CORPORATION (FI) | 2004-11-25 | — | — | US | disclosed |
| EP-1412343-A1 | NEW COMPOUNDS, WHICH ARE POTENT INHIBITORS OF NA+/CA2+ EXCHANGE MECHANISM AND ARE USEFUL IN THE TREATMENT OF ARRHYTHMIAS | ORION CORPORATION (FI) | 2004-04-28 | — | — | EP | disclosed |
| WO-2003006452-A1 | NEW COMPOUNDS, WHICH ARE POTENT INHIBITORS OF NA+/CA2+ EXCHANGE MECHANISM AND ARE USEFUL IN THE TREATMENT OF ARRHYTHMIAS | ORION CORPORATION (FI) | 2003-01-23 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040235905-A1 | Compounds, which are potent inhibitors of na+ / ca2+ exchange mechanism and are useful in the treatment of arrhythmias | CACNA1E, KCNN4, RYR2 | MAPT 4853/4885MAPK1 878/4885HSPB1 2699/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.